Technology company Tempus AI Inc (NASDAQ:TEM) said on Thursday that it has been chosen by the Advanced Research Projects Agency for Health (ARPA-H) to provide contract research organisation (CRO) and testing services for the ADAPT (Advanced Analysis for Precision Cancer Therapy) programme.

This initiative focuses on adaptive precision cancer therapies targeting non-small cell lung, breast, and colorectal cancers.

The programme aims to address tumour evolution and therapy resistance by integrating computational models, novel biomarkers, and innovative clinical trial designs. Tempus will contribute its AI-enabled diagnostics, including xE, xR, xF+, and xM, and leverage its CRO, Compass, to manage trial operations across all sites.

Additionally, Tempus will use its data integration capabilities to collect and harmonise study data for ARPA-H. The ADAPT programme seeks to identify resistant tumour traits, predict effective therapies at each treatment stage, and improve long-term patient outcomes. Tempus's involvement is intended to accelerate the development of personalised, adaptive cancer treatments.